Listed

NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 12, 2022 and accepted by EDGAR at May 12, 2022, 20:26 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-01-01 to 2022-03-31$36.6kus-gaap:Revenues
Revenue6 months2021-10-01 to 2022-03-31$70.3kus-gaap:Revenues
Cost of revenue3 months2022-01-01 to 2022-03-31$72.8kus-gaap:CostOfRevenue
Cost of revenue6 months2021-10-01 to 2022-03-31$119.7kus-gaap:CostOfRevenue
Gross profit3 months2022-01-01 to 2022-03-31−$36.2kus-gaap:GrossProfit
Gross profit6 months2021-10-01 to 2022-03-31−$49.3kus-gaap:GrossProfit
Research and development3 months2022-01-01 to 2022-03-31$1.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2021-10-01 to 2022-03-31$2.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$3.1mus-gaap:OperatingIncomeLoss
Operating income6 months2021-10-01 to 2022-03-31−$5.9mus-gaap:OperatingIncomeLoss
Net income3 months2022-01-01 to 2022-03-31−$3.1mus-gaap:NetIncomeLoss
Net income6 months2021-10-01 to 2022-03-31−$5.9mus-gaap:NetIncomeLoss
Basic EPS3 months2022-01-01 to 2022-03-31−$0.19us-gaap:EarningsPerShareBasic
Basic EPS6 months2021-10-01 to 2022-03-31−$0.37us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-01-01 to 2022-03-3116,189,867 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2021-10-01 to 2022-03-3115,794,880 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2021-10-01 to 2022-03-31−$5.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2021-10-01 to 2022-03-31$154.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$12.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$13.4mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$14.1mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$810.2kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$966.3kus-gaap:Liabilities
Shareholders' equityAt period end2022-03-31$13.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-22-025966. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.